Phys Clinical Cases · dermatological
Skin Signs OF Internal Malignancy — DCE Clinical Case
DCE long-case and short-case station for Skin Signs OF Internal Malignancy.
On this page & tools
Target exams
Skin Signs OF Internal Malignancy — Clinical Case
DCE Long Case
Patient brief
Patient: A middle-aged or older adult with multimorbidity and a presentation centred on Skin Signs OF Internal Malignancy. [1]
Presenting complaint: Subacute or acute symptoms referable to Skin Signs OF Internal Malignancy, with enough detail to force prioritisation. [1] [2]
Past history: Common cardiometabolic and organ comorbidities that interact with the plan. [2]
Medications: A polypharmacy list that includes at least one interaction or dosing issue. [2]
Examination: Key positives and critical negatives for dangerous differentials. [1]
Investigations: A small set of results that change management. [1] [2]
Tasks
- Present a prioritised problem list. [1]
- Defend investigations and immediate therapy. [1] [2]
- Provide safety-net and follow-up advice. [2]
Model discussion points
- Working diagnosis and acuity. [1]
- Differentials and discriminators. [2]
- Treatment sequence and monitoring. [1] [2] [3]
- Multimorbidity and communication. [2]
You have read the opening of this clinical case. The complete unit — every section and its primary-source references — is part of the Physician Medicine fellowship atlas.
References8Show ledgerHide ledger
- [1]Alsheyyab J, Al-Mahasneh HA, Al-Khalaileh SY, Hasan HA, et al. Pancreatic Adenocarcinoma Presented as Paraneoplastic Dermatomyositis Complicated with Rhabdomyolysis: Case Report and Review Am J Case Rep, 2026.PMID 42397795
- [2]Sadam Zeb M, Mian UU, Khan K, Gulalay A, et al. Hidden in Plain Sight: Systemic Mastocytosis Manifesting as Isolated Hepatosplenomegaly in the Absence of Cutaneous and Classical Manifestations-A Case Report and Literature Review Clin Case Rep, 2026.PMID 42368359
- [3]Raguraman V, Mysinger M, Verma M, Mohiyuddin S, et al. Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease Front Immunol, 2026.PMID 42367798
- [4]Mejias C, Morgan RL, Arora SS, et al. ACR Appropriateness Criteria® Staging and Follow-Up of Melanoma J Am Coll Radiol, 2026.PMID 41823939
- [5]Takai T, Kadono T, Fujimoto N, Yoden E, et al. Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Squamous Cell Carcinoma 2025 J Dermatol, 2026.PMID 41368724
- [6]van de Berg DJ, Vriens MR, van Santen HM, Seur A, et al. Core Outcome Set of the Surgical Treatment of Differentiated Thyroid Carcinoma: International Consensus by Delphi Study Thyroid, 2025.PMID 41203254
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922